Glen Clova Scientific raises £4M to combat autoimmune diseases

The biotech is developing drugs based on research pioneered by Dr John Foerster and his team at the University of Dundee.
Glen Clova Scientific raises £4M to combat autoimmune diseases

Scottish biotech startup Glen Clova Scientific has closed a £4M Seed round, led by Norcliffe Capital. The investment will be made in two tranches of £2.5m and £1.5m.

Founded in 2022 as a spin out from the University of Dundee, GCS is developing drugs for chronic inflammatory and autoimmune disorders. The funding enables the Company to advance preclinical development of three initial drugs: GCS001 for treatment of senile pruritus, GCS002 for atopic dermatitis and GCS003 for eczema and asthma. 

The company has developed a technology platform underpinning its product development pipeline and GCS’ technology will be exploited in several non-pharmaceutical markets through partnerships. DSW Ventures, TRICAPITAL Angels and Scottish Enterprise also participated in the round.

Steven Powell, co-founder of Glen Clova Scientific, commented: “Our GCS VLP platform has the potential to produce a new generation of active biologic drugs offering both enhanced performance and a simpler, more cost-effective manufacturing process compared with existing biologic drugs.

"We believe that these drugs can have a significant impact on large patient populations with poorly met medical needs. We are delighted to have attracted support from a syndicate of high-quality, experienced investors to finance the development of our drug development pipeline and the continued expansion of our proprietary technology platform.”

Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.